The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Tocilizumab is a humanized monoclonal antibody which targets and inhibits interleukin-6 (IL-6) and has demonstrated efficacy in treating diseases associated with hyper-inflammation. Data are suggestive of tocilizumab as a potential treatment for patients with COVID-19 infection....

Full description

Bibliographic Details
Main Authors: Aoife Cotter, Deborah Wallace, Cormac McCarthy, Eoin Feeney, Lorraine O’Neill, John Stack, Geraldine McCarthy, Rabia Hussain, Elena Alvarez Barco, Peter Doran, Patrick Mallon
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
protocol
Tocilizumab
Immunology
Therapeutics
Online Access:http://link.springer.com/article/10.1186/s13063-020-04680-w

Internet

http://link.springer.com/article/10.1186/s13063-020-04680-w

Similar Items